Aquilion One CT Family Aids TAVR Planning

Toshiba showcases how CT Is a cost effective solution to helping make TAVR procedures more efficient for patients at ACC

A 3-D CT reconstruction of a TAVR run-off image to assess the femoral access route using Toshiba's Aquillion One and Vital Images advanced visualization technologies.

April 15, 2016 — Accurate and precise anatomical information is crucial to successful transcatheter aortic valve replacement (TAVR) procedures, and Toshiba America Medical Systems said its Aquilion One family of CT systems can deliver the visualization he technologies needed during planning. The system gives clinicians the image detail and system flexibility required for planning and performing these procedures. Toshiba showcased these abilities at this year’s American College of Cardiology (ACC) annual meeting April 2-4.

The Aquilion One family features the industry’s thinnest slices of 0.5 mm and comes in three configurations, including the Aquilion One 320, Aquilion One 640 and Aquilion One Vision Edition. To improve workflow and make TAVR planning more efficient, the systems feature wide detector volumetric cardiac capabilities and Toshiba’s Adaptive Diagnostics technology like the variable helical pitch (vHP), which automatically changes from an ECG-gated to a non-ECG-gated acquisition during a single helical scan, reducing IV contrast and radiation dose. Vital’s CT TAVR planning application can also be utilized to visualize and measure vascular anatomy for the evaluation, treatment and follow up of aortic vascular disorders.

All Aquilion One family systems are XR-29 compliant and come standard with Toshiba’s complete suite of dose reduction technologies, including AIDR 3D Enhanced.

“Toshiba’s Aquilion One family plays a critical role in TAVR planning, with its unique ability to acquire anatomical and functional data in a single heartbeat,” said Dominic Smith, senior director, CT, PET/CT, and MR business units, Toshiba. “The Aquilion One Family offers clinical and operational solutions that make work flow and contribute to many cost efficiencies by making pre-procedure TAVR planning more efficient.”

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.